3 Stocks Raising The Health Care Sector Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 0 points (0.0%) at 18,120 as of Tuesday, June 23, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,606 issues advancing vs. 1,375 declining with 175 unchanged.

The Health Care sector currently sits down 0.5% versus the S&P 500, which is down 0.1%. Top gainers within the sector include Novavax ( NVAX), up 8.2%, Smith & Nephew ( SNN), up 1.7%, Allergan ( ACT), up 1.2%, Allergan ( AGN), up 1.2% and Bristol-Myers Squibb Company ( BMY), up 0.8%. On the negative front, top decliners within the sector include Alnylam Pharmaceuticals ( ALNY), down 1.3%, Novo Nordisk A/S ( NVO), down 1.2%, Biogen ( BIIB), down 0.6%, Teva Pharmaceutical Industries ( TEVA), down 0.6% and Abbott Laboratories ( ABT), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Health Care sector higher today. As of noon trading, Vertex Pharmaceuticals is up $2.00 (1.6%) to $131.03 on average volume. Thus far, 697,908 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $129.39-$131.26 after having opened the day at $129.57 as compared to the previous trading day's close of $129.03.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals has a market cap of $31.2 billion and is part of the drugs industry. Shares are up 8.6% year-to-date as of the close of trading on Monday. Currently there are 8 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Perrigo ( PRGO) is up $2.84 (1.5%) to $187.70 on light volume. Thus far, 561,013 shares of Perrigo exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $185.79-$190.67 after having opened the day at $185.95 as compared to the previous trading day's close of $184.87.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Perrigo has a market cap of $27.1 billion and is part of the drugs industry. Shares are up 10.6% year-to-date as of the close of trading on Monday. Currently there are 4 analysts who rate Perrigo a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Perrigo as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Perrigo Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, UnitedHealth Group ( UNH) is up $2.00 (1.7%) to $122.25 on average volume. Thus far, 2.3 million shares of UnitedHealth Group exchanged hands as compared to its average daily volume of 3.9 million shares. The stock has ranged in price between $121.01-$122.77 after having opened the day at $121.37 as compared to the previous trading day's close of $120.25.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. UnitedHealth Group has a market cap of $114.5 billion and is part of the health services industry. Shares are up 18.9% year-to-date as of the close of trading on Monday. Currently there are 14 analysts who rate UnitedHealth Group a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates UnitedHealth Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full UnitedHealth Group Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

More from Markets

Trump Tariff Threat, Deutsche Bank, Elon Musk and Apple - 5 Things You Must Know

Trump Tariff Threat, Deutsche Bank, Elon Musk and Apple - 5 Things You Must Know

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Automakers Slump as Trump Launches National Security Probe into US Car Imports

Automakers Slump as Trump Launches National Security Probe into US Car Imports

Deutsche Bank Confirms Massive Job Cuts as New CEO Christian Sewing Plants Flag

Deutsche Bank Confirms Massive Job Cuts as New CEO Christian Sewing Plants Flag

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market